Corrigendum to "Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial" [J. Bone Oncol. 35 (2022) 100441]. [PDF]
J Bone OncolYue J, Sun W, Li S.
europepmc +1 more source
Beyond bone effects: the role of denosumab in muscle Health - A systematic review. [PDF]
Aging Clin Exp ResCeolin C +5 more
europepmc +1 more source
Real-world effectiveness of denosumab compared to teriparatide in patients with severe osteoporosis. [PDF]
Front Endocrinol (Lausanne)Birtolo MF +18 more
europepmc +1 more source
Denosumab Plus Immune Checkpoint Inhibitors in Bone Metastases From Solid Tumors. [PDF]
Cancer ControlWang N, Song F, Li X, Chen H.
europepmc +1 more source
Mandibular osteomyelitis induced by denosumab administration: Case report. [PDF]
Medicine (Baltimore)Liu C +4 more
europepmc +1 more source
Conversion to Complete, Parenchyma-Sparing Resection after Prolonged Denosumab for Bilateral Multifocal Pulmonary Metastases from Giant Cell Tumor of Bone: A Case Report. [PDF]
Ann Thorac Cardiovasc SurgOmura S, Sasaki A, Anazawa U, Eguchi K.
europepmc +1 more source
Filling the treatment gaps in osteoporosis: osteoimmunology as a new frontier. [PDF]
EBioMedicineeBioMedicine.
europepmc +1 more source
Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database. [PDF]
Front Endocrinol (Lausanne)Bai H +5 more
europepmc +1 more source
Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation. [PDF]
Sci RepCho YH, Byun SE, Lee HH.
europepmc +1 more source